Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial
In the main part, 220 children across Burkina Faso, Mali, Cote d'Ivoire, Gabon, and DR Congo had PCR-corrected cure on day 29 of 97 of 98 (99%) with ganaplacide plus lumefantrine versus 98 of 99 (99%) with artemether-lumefantrine, a non-inferior result, and vomiting was 29% versus 11%. Ganaplacide is a new non-artemisinin antimalarial class, and a phase 3 trial followed (NCT05842954).
The Lancet Infectious Diseases · 10.1016/s1473-3099(26)00492-5